Eric Furfine
Bristol-Myers Squibb
50 Papers
400 Citations
Eric Furfine is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Fusion protein & Serum albumin. The author has an hindex of 14, co-authored 50 publications.
Chat about Author
Papers
Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface
Michael M. Schmidt,Sharon A. Townson,Amy Jada Andreucci,Bracken M. King,Emily Belcher Schirmer,Alec J. Murillo,Christian Dombrowski,Alison Tisdale,Patricia Lowden,Allyson Masci,Joseph Kovalchin,David V. Erbe,K. Dane Wittrup,Eric Furfine,Thomas M. Barnes +14 more
TL;DR: It is found that fatty acids (FAs) compete with FcRn, revealing a clash between ligand binding and recycling, and that high-affinity HSA variants have significantly increased circulating half-lives in mice and monkeys.
119
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher,Christopher Sweeney,Kyri Papadopoulos,Amita Patnaik,Elena G. Chiorean,Alain C. Mita,Kamalesh Kumar Sankhala,Eric Furfine,Jochem Gokemeijer,Lisa Iacono,Cheryl Eaton,Bruce A. Silver,Monica M. Mita +12 more
TL;DR: The absence of severe toxicities at the MTD, demonstration of plasma drug concentrations active in preclinical models, and clinical pharmacodynamic evidence of VEGFR-2 inhibition warrant further development of CT-322 and suggest strong potential for Adnectin-based targeted biologics.
93
A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor
Stuart Emanuel,Linda Engle,Ginger Chao,Rong-Rong Zhu,Carolyn Cao,Zheng Lin,Aaron P. Yamniuk,Jennifer Hosbach,Jennifer Brown,Elizabeth Fitzpatrick,Jochem Gokemeijer,Paul E. Morin,Brent Morse,Irvith M. Carvajal,David Fabrizio,Martin C. Wright,Ruchira Das Gupta,Michael L. Gosselin,Daniel Cataldo,Rolf Ryseck,Michael L. Doyle,Tai W. Wong,Raymond T Camphausen,Cload Sharon T,H. Nicholas Marsh,Marco M. Gottardis,Eric Furfine +26 more
TL;DR: Efficient engineering of bispecific Adnectin targeting epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR), two transmembrane receptors that mediate proliferative and survival cell signaling in cancer, is demonstrated.
82
Patent
Serum albumin binding molecules
Michael L. Gosselin,David Fabrizio,Joanna F. Swain,Tracy S. Mitchell,Ray Camphausen,Cload Sharon T,Eric Furfine,Paul E. Morin,Ranjan Mukherjee,Taylor Simeon I +9 more
- 03 May 2011
TL;DR: In this article, an antibody-like protein based on the 10Fn3 domain was proposed for use in diagnostic and therapeutic applications, which was shown to be able to bind to serum albumin.
55
Patent
Vegf pathway blockade
John Mendlein,Eric Furfine +1 more
- 01 Feb 2008
TL;DR: The use of VEGF-A as a biomarker for determining an effective dosage and predicting the efficacy of these proteins was proposed in this paper. But, the use of this biomarker was not considered in this paper.
45